New breast cancer drug candidate BL0175 enters first human safety trial
NCT ID NCT07366632
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 1 study will test a single injection of BL0175, a new polymer-linked form of the breast cancer drug fulvestrant, in 27 healthy postmenopausal women. The goal is to see if BL0175 is safe and how long it stays in the body compared to standard fulvestrant. This is an early-stage trial that does not involve cancer patients and will not measure whether the drug works against tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- BL0175 (a polymer-linked form of fulvestrant)
- What this could lead to
- If successful, this early study could pave the way for a longer-lasting version of fulvestrant, potentially reducing injection frequency for breast cancer treatment.
- What could go wrong
- This is a very early Phase 1 trial with only 27 healthy volunteers, not patients. It only tests safety and drug levels, not whether the drug works against cancer. Many early-stage drugs fail to show benefit later.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POSTMENOPAUSAL WOMEN are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can magnetic pulses calm an overactive bladder?
- Which cervical prep eases hysteroscopy for postmenopausal women?
- Knee replacement may not fully restore balance in older women
- Could a whey protein drink boost heart and brain health in menopause?
- Anti-Aging drug and football drills join forces to fight brittle bones
- Lifting weights may boost heart health in menopause